Lung Transplantation 1: An Overview - Recipient Evaluation and Procedures

2019 ◽  
Author(s):  
Hilary J Goldberg
Keyword(s):  
Quality Of Life ◽  
Lung Transplantation ◽  
Therapeutic Option ◽  
Organ Transplant ◽  
Therapeutic Interventions ◽  
Solid Organ ◽  
Progression Of Disease ◽  
Potential Benefits ◽  
Prognostic Data

Lung transplantation is a potential therapeutic option for select candidates with advanced lung disease who have exhausted other therapeutic interventions and in whom survival and/or quality of life are threatened by the progression of disease. Although lung transplantation may confer substantial benefits on recipients, the median survival after lung transplantation according to the most recent registry data is only 5.7 years, substantially shorter than that for other solid-organ transplant cohorts. As a result, the available prognostic data for potential recipients in the absence of lung transplantation, the risks of transplantation, and the potential benefits in terms of survival and quality of life should be reviewed in detail when considering this intervention. This review discusses candidates for lung transplantation, timing of transplantation, organ donors and donor-recipient matching, transplantation procedures, and transplantation outcomes.  This review contains 4 figures, 7 tables, and 70 references. Keyword: Lung transplant, recipient, donor, brain-dead donor, cadaver, cystic fibrosis, bronchiectasis

Lung Transplantation 2: Care of the Lung Transplant Recipient

2019 ◽  
Author(s):  
Hilary J Goldberg
Keyword(s):  
Lung Transplantation ◽  
Lung Transplant ◽  
Therapeutic Option ◽  
Organ Transplant ◽  
Bronchiolitis Obliterans Syndrome ◽  
Therapeutic Interventions ◽  
Solid Organ ◽  
Progression Of Disease ◽  
Transplantation Outcomes

Lung transplantation is a potential therapeutic option for select candidates with advanced lung disease who have exhausted other therapeutic interventions and in whom survival and/or quality of life are threatened by the progression of disease. Although lung transplantation may confer substantial benefits on recipients, the median survival after lung transplantation according to the most recent registry data is only 5.7 years,1 substantially shorter than that for other solid-organ transplant cohort. This review discusses posttransplantation management, transplantation outcomes, and posttransplanation complications.  This review contains 5 figures, 6 tables, and 38 references.  Keywords: Lung transplant, postoperative period, immunosuppression, survival, complications, allograft rejection, infection, bronchiolitis obliterans syndrome, lung infection

Baseline Quality of Life and Anxiety in Solid Organ Transplant Recipients: A Pilot Study

2006 ◽  
Vol 32 (12) ◽  
pp. 1480-1485 ◽  
Author(s):  
FIONA O'REILLY ◽  
CARMEN TRAYWICK ◽  
MICHELLE L. PENNIE ◽  
JOVONNE K. FOSTER ◽  
SUEPHY C. CHEN
Keyword(s):  
Quality Of Life ◽  
Pilot Study ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

Baseline Quality of Life and Anxiety in Solid Organ Transplant Recipients

2006 ◽  
Vol 32 (12) ◽  
pp. 1480-1485 ◽  
Author(s):  
FIONA OʼREILLY ◽  
CARMEN TRAYWICK ◽  
MICHELLE L. PENNIE ◽  
JOVONNE K. FOSTER ◽  
SUEPHY C. CHEN
Keyword(s):  
Quality Of Life ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

scholarly journals Cytomegalovirus in Lung Transplant

2021 ◽  
Vol 05 (02) ◽  
pp. 1-1
Author(s):  
Justin P. Rosenheck ◽  
◽  
Mena M B otros ◽  
David R Nunley ◽  
◽  
...  
Keyword(s):  
Lung Transplantation ◽  
Lung Transplant ◽  
Therapeutic Option ◽  
Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Ongoing Research ◽  
Complex Patients ◽  
Lung Transplant Recipients ◽  
New Generation

Lung transplantation is a therapeutic option for patients with advanced lung diseases. Lung transplant outcomes have improved over time with improvements in the management of these complex patients. Cytomegalovirus is a common opportunistic organism affecting all solid organ transplant recipients. Characteristics unique to lung transplantation can make this virus difficult to manage, with myriad complications including graft failure and death. Ongoing research into and understanding of cytomegalovirus has opened exciting new avenues of management. We discuss the various manifestations of CMV related pathologies in the lung transplant recipient. We discuss current mainstays of risk stratification, diagnosis, and treatment, as well as present new and evolving concepts. Current medications are highly effective at preventing and treating CMV manifestations, but may be poorly tolerated. A new generation of therapies carry the promise of efficacy, with a greater safety profile and improved tolerance of adverse effects. We discuss host-virus immune interactions, specifically how these can be utilized in clinical practice to individualize the cytomegalovirus related care of lung transplant recipients. Finally, we turn our attention to the near horizon as we continue to evolve the care of this unique population.

Quality of life as a predictor of morbidity, mortality, and resource utilization after solid-organ transplant

2001 ◽  
Vol 33 (1-2) ◽  
pp. 1886 ◽  
Author(s):  
A.L Phillips ◽  
E.L Walker ◽  
J.E Martin ◽  
M.R First ◽  
D.W Hanto ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Resource Utilization ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ

Pleuroparenchymal fibroelastosis: from diagnosis to pulmonary rehabilitation

2021 ◽  
Vol 14 (6) ◽  
pp. e236754
Author(s):  
Ipek Candemir ◽  
Pinar Ergun ◽  
Nese Demir
Keyword(s):  
Quality Of Life ◽  
Lung Transplantation ◽  
Pulmonary Rehabilitation ◽  
Therapeutic Option ◽  
Psychological Status ◽  
Pleuroparenchymal Fibroelastosis ◽  
Uncommon Disease

Pleuroparenchymal fibroelastosis (PPFE) is an uncommon disease of which diagnosis should be established multidisciplinary fashion and has no effective medical therapy. Pulmonary rehabilitation (PR) can be applied, but lung transplantation is the only therapeutic option. There have been few reported cases or studies showing the efficacy of PR in patients with PPFE in the literature. We present our multidisciplinary PR programme including confirmation of the diagnosis and a structured follow-up programme in two PPFE patients. In both cases, after multidisciplinary PR the diagnoses were confirmed and body composition, quality of life, exercise capacity and psychological status improved and some improvements preserved for 6–12 months. They underwent lung transplantation about 2 years after PR. Patients with PPFE should be directed and encouraged to participate in comprehensive multidisciplinary PR programmes. Long-term structured follow-up programmes could preserve the improvements, increase adherence and save time while waiting on the transplant list.

Sign in / Sign up

Export Citation Format

Share Document